8RK Stock Overview

Develops, manufactures, sells, and markets animal and human health medicine products in Spain, rest of European Union, and internationally. More details

8RK fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	2/6
Financial Health	3/6
Dividends	0/6

Rewards

Trading at 87.1% below our estimate of its fair value

Earnings are forecast to grow 85.82% per year

Became profitable this year

Risk Analysis

Interest payments are not well covered by earnings

Does not have a meaningful market cap (€23M)

Large one-off items impacting financial results

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Labiana Health, S.A. Competitors

Apontis Pharma

XTRA:APPH

€91.2m

PharmaSGP Holding

XTRA:PSG

€280.9m

MPH Health Care

DB:93M1

€106.2m

Dermapharm Holding

XTRA:DMP

€2.1b

Price History & Performance

Summary of share price highs, lows and changes for Labiana Health
Historical stock prices
Current Share Price	€3.16
52 Week High	€3.16
52 Week Low	€1.62
Beta	-0.49
1 Month Change	17.04%
3 Month Change	12.86%
1 Year Change	92.68%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	34.47%

Recent updates

Shareholder Returns

	8RK	DE Pharmaceuticals	DE Market
7D	9.0%	0.1%	1.7%
1Y	92.7%	-19.6%	12.8%

Return vs Industry: 8RK exceeded the German Pharmaceuticals industry which returned -19.6% over the past year.

Return vs Market: 8RK exceeded the German Market which returned 12.8% over the past year.

Price Volatility

Is 8RK's price volatile compared to industry and market?
8RK volatility
8RK Average Weekly Movement	4.8%
Pharmaceuticals Industry Average Movement	5.1%
Market Average Movement	6.3%
10% most volatile stocks in DE Market	13.0%
10% least volatile stocks in DE Market	3.1%

Stable Share Price: 8RK has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: 8RK's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1958	364	Manuel Ortega	www.labiana.com

Labiana Health, S.A. develops, manufactures, sells, and markets animal and human health medicine products in Spain, rest of European Union, and internationally. The company offers anesthetics-sedative, anti-infective, anti-inflammatory, antiparasitic, hormonal, and nutritional products; metabolism regulators; and vitamin products. It also provides sterile, lyophilized, and biological formats; and Fosfomycin trometamol under the Fosfomicina Labiana brand name.

Labiana Health, S.A. Fundamentals Summary

How do Labiana Health's earnings and revenue compare to its market cap?
8RK fundamental statistics
Market cap	€22.81m
Earnings (TTM)	€253.45k
Revenue (TTM)	€67.37m

90.0x

P/E Ratio

0.3x

P/S Ratio

Is 8RK overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
8RK income statement (TTM)
Revenue	€67.37m
Cost of Revenue	€26.43m
Gross Profit	€40.94m
Other Expenses	€40.69m
Earnings	€253.45k

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.036
Gross Margin	60.77%
Net Profit Margin	0.38%
Debt/Equity Ratio	328.6%

How did 8RK perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/08 05:47
End of Day Share Price	2025/05/07 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Labiana Health, S.A. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Alfredo Echevarria Otegui	Lighthouse-IEAF Servicios de Analisis
Luis Esteban Arribas	Lighthouse-IEAF Servicios de Analisis

Labiana Health DB:8RK Stock Report